Cavoley (pegfilgrastim)

Where it stands

Cavoley (pegfilgrastim) is authorised in the EU. The marketing authorisation holder is CuraTeQ Biologics s.r.o. The European Commission decision is dated 2026-09-25, following a positive CHMP opinion on 2026-07-23. Both milestones are official records.

The approved indication is to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy. Chronic myeloid leukaemia and myelodysplastic syndromes are excluded. The therapeutic area is recorded as neutropenia.

The gap between opinion and decision is 64 days, about nine weeks. That is consistent with the usual process, in which the Commission adopts a legally binding decision based on the CHMP opinion. The records give no information on launch timing, pack presentations or national reimbursement status.

Regulatory pathway and designations

The records label Cavoley as a biosimilar. In the EU, a biosimilar is assessed centrally by the EMA and CHMP against an already authorised reference biologic. The standard expectation is a demonstration of similarity in quality, biological activity, safety and efficacy. The records do not name the reference product and do not describe the data package, so neither can be assessed here.

Cavoley also carries the additional monitoring designation. The records do not state why it was applied, so no reason should be inferred.

The same substance is already present elsewhere. Five other pegfilgrastim products are listed as authorised in the EU: Nylaspeg, Ziextenzo, Grasustek, Fulphila and Dyrupeg. Armlupeg is listed as approved in the US. The records do not say which of these are biosimilars, nor do they link any of them to CuraTeQ. Cavoley therefore enters an EU pegfilgrastim segment that already has several authorised products.

Safety and pharmacovigilance

The records contain no product-specific safety data. They give no adverse-event profile, risk management plan content, post-authorisation commitments or conditions of the authorisation, so none are described here.

The one safety-relevant fact in the records is the additional monitoring status. In general, products with this status are subject to intensified safety surveillance. They are identified by a black inverted triangle in the product information, together with a statement encouraging healthcare professionals and patients to report suspected adverse reactions. Prescribers and pharmacovigilance teams should expect this labelling for Cavoley.

Reporting suspected adverse reactions for a biosimilar should also include the product name and batch number. This helps traceability among similar biologics, though the records do not describe any Cavoley-specific traceability measures.

What to watch

The records do not include forward-looking regulatory dates, so none are stated here. The approved EU product information, the EPAR and the risk management plan summary, once published by the EMA, would be the primary sources for the missing detail. These include the reference product, the clinical and quality basis, the formulations and any risk-minimisation measures.

Points worth tracking from the records alone are whether CuraTeQ pursues further regulatory activity for pegfilgrastim, since the US entry Armlupeg is not linked to the company in the records. Also worth tracking are the commercial launch of Cavoley in individual EU member states and any change to its additional monitoring status. The records do not say when, or whether, the status will be reviewed.